Pfizer Submits Crizotinib NDA with FDA; Abbott to File Companion Dx Approval Application Soon
May 18, 2011
Pfizer Submits Crizotinib NDA with FDA; Abbott to File Companion Dx Approval Application Soon
Pfizer completed submission of its NDA for the ALK-inhibiting non-small cell lung cancer drug crizotinib, and was granted a priority review from the FDA. Meantime, Abbott Molecular plans to submit "shortly" a premarket approval application for a commercial companion diagnostic that will pick out best responders to crizotinib.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Abbott Seeks Approval in US, Japan for Dx to Pick Best Responders to Pfizer's Crizotinib
May 25, 2011 / Pharmacogenomics Reporter - Pfizer, Abbott Plan Parallel Filing for FDA Approval of NSCLC Drug Crizotinib, FISH Test
January 19, 2011 / Pharmacogenomics Reporter - Early Data Convinces Some Oncologists to Treat ROS1-Positive NSCLC Patients with Xalkori
June 6, 2012 / Pharmacogenomics Reporter - FDA OK for Pfizer's Xalkori and Companion Dx Highlights Upside for PGx Strategies in Drug Development
September 7, 2011 / Pharmacogenomics Reporter - Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO
June 9, 2010 / Pharmacogenomics Reporter